A Breath of Fresh Air: Novel Treatments That Address the Inflammatory Component of Non-Cystic Fibrosis Bronchiectasis

Overview

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by an educational grant from Insmed.

Activity Description

Non-cystic fibrosis bronchiectasis (NCFBE) is a heterogenous and increasingly prevalent chronic pulmonary disease that is associated with high morbidity and mortality. It is characterized by irreversibly damaged and dilated bronchi, and has a broad spectrum of clinical presentations, ranging from asymptomatic radiological changes detected incidentally to chronic sputum production and recurrent exacerbations. There are numerous etiologies that can induce or contribute to the pathophysiological processes that result in NCFBE. The concomitant presence of chronic obstructive pulmonary disease increases the use of healthcare resources and is associated with poorer health. Optimal management of NCFBE requires an individualized approach. Effective therapies surrounding each component of the pathophysiological processes (ie, inflammation, infection, mucociliary clearance) may be required to disrupt the “vicious cycle” to achieve desirable outcomes. Currently, there are no therapies approved by the US Food and Drug Administration for the treatment of NCFBE, but research and development of novel targeted agents are ongoing, including those that target neutrophilic inflammation.

Target Audience

The intended audience for this activity is pulmonologists, radiologists, internists, family medicine physicians, nurse practitioners, physician associates, and other healthcare professionals involved in the management of patients with noncystic fibrosis bronchiectasis (NCFBE).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Describe the pathophysiologic implications of noncystic fibrosis bronchiectasis (NCFBE), including the effects of persistent neutrophilic inflammation.
• Examine evidence- and guideline-based diagnostic measures that can successfully identify patients with NCFBE.
• Analyze clinical trial data regarding emerging therapies that target the inflammatory component of NCFBE.

Activity Chair

Anne E. O'Donnell, MD, FACP, FCCP
Professor of Medicine
Chief, Division of Pulmonary Critical Care and Sleep Medicine
Georgetown University Medical Center
Washington, DC

Faculty

Charles L. Daley, MD, FCCP
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor of Medicine
National Jewish Health
University of Colorado School of Medicine and
Icahn School of Medicine at Mt. Sinai
Denver, CO

Mark Metersky, MD, FCCP
Professor and Chief
Division of Pulmonary, Critical Care and Sleep Medicine
University of Connecticut School of Medicine
Farmington, CT

Patient Advocate

Mary Kitlowski
No relevant financial relationships to disclose.

Planner/Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Accreditation

In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, June 15, 2023, to June 14, 2024.

How to Participate in This Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant financial relationship(s)

Charles L. Daley, MD, FCCP
Advisor: Hyfe, Insmed, Juvabis

Mark Metersky, MD, FCCP
Consultant: Insmed, Renovion, Zambon
Speaker Contracted by Ineligible Company: Insmed, Tactile Medical
Independent Research Contractor: Armata, Insmed

Anne E. O'Donnell, MD, FACP, FCCP
Consultant: Electromed, Insmed, Zambon
Independent Research Contractor: Insmed, Zambon

Patient Advocate reports the following relevant financial relationship(s)

Mary Kitlowski
No relevant financial relationships to disclose.

Planner/Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com